Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy and Safety of Infliximab in Chinese Subjects With Active Ulcerative Colitis

NCT01551290 is registered in ClinicalTrials.gov with Xian-Janssen Pharmaceutical Ltd. as lead sponsor.

NCT NCT01551290
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01551290 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy and Safety of Infliximab in Chinese Subjects With Active Ulcerative Colitis
Lead sponsor
Xian-Janssen Pharmaceutical Ltd.
Phase
Phase 3
Overall status
Completed
Start date
April 30, 2012
Completion date
October 31, 2014
Enrollment
99 (actual)
Sites
7

Conditions

As the registry lists them; a condition with its own page is linked.

ulcerative colitis